SCYNEXIS to Participate in the Cantor Antibiotics Summit

SCYNEXIS to Participate in the Cantor Antibiotics Summit

JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled “Novel Ways to Treat and/or Address Infections” at the Cantor Antibiotics Summit at the Omni Berkshire Hotel, New York, on Wednesday, January 17, 2018 at 12:15 p.m. ET.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company’s lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit

TravelWireNews Chatroom for Readers (join us)


Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
[email protected]

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
[email protected]  

Cision View original content:


Related Links

%d bloggers like this: